Biotech features clinical-stage trial failures rates that are above 90% and that makes investing in the industry treacherous. If you don't do your homework, you can wind up losing a lot of money. So, with that in mind, I went searching for hot biotech stocks that deserve a closer look and discovered Madrigal Pharmaceuticals (NASDAQ: MDGL)and NuCana Plc(Nasdaq: NCNA).
Are these two companies worth adding to your portfolio?Better Know Biotech: 2 Stocks You've Got to Know About
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться